ALMS Alumis Inc.
Alumis Inc. (ALMS) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.69 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.1% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Alumis Inc.
Alumis Inc. is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's product candidate includes ESK-001. Alumis Inc. is based in SOUTH SAN FRANCISCO, Calif.
Sector
Healthcare
Industry
Biotechnology